摘要
异常基因重排在肿瘤的发展中频繁出现。H3赖氨酸27三甲基化组蛋白(H3K27me3)对许多基因产生了抑制性遗传外标记。UTX和JMJD3是唯一的两个组蛋白去甲基化酶,它们通过将H3K27me2去甲基化变成H3K27me2或者H3K27me1来激活基因表达。现代研究表明,这两种蛋白功能失调与多种组织样肿瘤化有很大关系。越来越多证据表明,靶向不同癌症中JMJD3或者UTX有显著治疗可能性。在此,我们将给出一个简要的关于癌症中JMJD3和UTX功能作用的综述,并评估靶向UTX与JMJD3的化合物和候选药。最后,我们讨论了癌症治疗中靶向UTX和JMJD3的一些模式。这篇综述将帮助研发新型疗法来消除或恢复UTX和JMJD3在癌症发病机制中的作用。
关键词: UTX
Current Medicinal Chemistry
Title:The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Volume: 23 Issue: 32
Author(s): Zhan Gang Xiao, Jing Shen, Lin Zhang, Long Fei Li, Ming Xing Li, Wei Hu, Zhi Jie Li, Chi Hin Cho
Affiliation:
关键词: UTX
摘要: Aberrant epigenetic reprogramming occurs frequently in the development of tumors. Histone H3 lysine 27 trimethylation (H3K27me3) exerts a repressive epigenetic mark on a large number of genes. UTX and JMJD3 are the only two histone demethylases which activate gene expression via demethylating H3K27me3 to H3K27me2 or H3K27me1. Current studies show that dysregulation of these two proteins are heavily linked to oncogenesis in various tissue types. Accumulating evidence suggested that there is remarkable therapeutic potential of targeting JMJD3 or UTX in different types of cancer. Herein, we shall give a brief review on the functional roles of JMJD3 and UTX in cancers and evaluate the available compounds and agents targeting UTX and JMJD3. Finally, we also discuss the several modalities that target UTX and JMJD3 for cancer therapy. This review will help to develop novel strategies to abolish or restore effects of UTX and JMJD3 in the pathogenesis of cancer.
Export Options
About this article
Cite this article as:
Zhan Gang Xiao, Jing Shen, Lin Zhang, Long Fei Li, Ming Xing Li, Wei Hu, Zhi Jie Li, Chi Hin Cho , The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives, Current Medicinal Chemistry 2016; 23 (32) . https://dx.doi.org/10.2174/0929867323666160725093522
DOI https://dx.doi.org/10.2174/0929867323666160725093522 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Air Pollution and Lung Cancer
Current Respiratory Medicine Reviews Glyoxalase 1 and 2 Enzyme Inhibitory Activity of 6-Sulfamoylsaccharin and Sulfocoumarin Derivates
Letters in Drug Design & Discovery Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Lymphoblastoid Cell Lines Models of Drug Response: Successes and Lessons from this Pharmacogenomic Model
Current Molecular Medicine Renal & Ocular Targets for Therapy in Wegeners Granulomatosis
Inflammation & Allergy - Drug Targets (Discontinued) Discovery of Novel Regulatory Peptides by Reverse Pharmacology: Spotlight on Chemerin and the RF-amide Peptides Metastin and QRFP
Current Protein & Peptide Science Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets In vitro Lipolysis: An Indispensable Tool for the Development of IVIVC of Lipid Based Drug Delivery Systems
Drug Delivery Letters Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings
Current Radiopharmaceuticals Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors)
Current Drug Targets Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha
Protein & Peptide Letters Genetic Engineering - A New Era for Cancer Immunotherapy?
Current Cancer Therapy Reviews The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment
Current Cancer Drug Targets Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design